Alliance pharmaceutique pancanadienne (APP) – dernières mises à jour
| État | Nombre total | Résumé |
|---|---|---|
| En négociation | 45 | Non liées à l’oncologie : 24 Liées à l’oncologie : 21 |
| Négociations envisagées | 20 | Non liées à l’oncologie : 11 Liées à l’oncologie : 9 |
| Négociations terminées | 898 | Avec lettre d’intention : 776 Sans entente : 122 |
| Négociations qui n’ont pas eu lieu | 113 |
Activités de l’APP dans les quatre dernières semaines
Voici les activités des quatre dernières semaines. Veuillez prendre note que le traitement de ces mises à jour peut prendre d’une à deux semaines.
Lettres d’engagement transmises au cours des quatre dernières semaines
| Marque | Fabricant | Indication | Date d’engagement |
|---|---|---|---|
| Zepzelca (active pTAP negotiation) | Jazz Pharmaceuticals Canada Inc. | For the treatment of adult patients with Stage III or metastatic small cell lung cancer (SCLC) who have progressed on or after platinum-containing therapy. | |
| Opzelura | Incyte Biosciences Canada Corporation | Atopic dermatitis | |
| Anzupgo | LEO Pharma Inc. | Chronic hand eczema | |
| Sarclisa | Sanofi Genzyme Canada | In combination with bortezomib, lenalidomide, and dexamethasone, for the treatment of patients with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant (ASCT). | |
| Epuris | Cipher | Acne Vulgaris | |
| Itovebi | Hoffmann-La Roche Ltd. | In combination with palbociclib and fulvestrant for the treatment of adult patients with endocrine resistant, PIK3CA-mutated, hormone receptor-positive (HR+) (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or meta | |
| Perjeta | Hoffmann-La Roche Ltd. | In combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with early-stage HER2-positive breast cancer | |
| Rebyota | Ferring Canada Inc. | Clostridioides difficile infection, prevention | |
| Alyftrek | Vertex Pharmaceuticals (Canada) Incorporated | Cystic fibrosis, F508del or responsive CFTR mutation, 6 years and older | |
| Lyvdelzi | Gilead Sciences Canada Inc. | For the treatment of primary biliary cholangitis (PBC), in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA alone, or as monotherapy in adults unable to tolerate UDCA. | |
| Quviviq | Idorsia Pharmaceuticals Canada Ltd. | Insomnia | |
| Ranvu | Apotex Inc. | Multiple Indications | |
| Carvykti | Janssen Inc. | (du) Multiple myeloma in adult patients who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and who are refractory to their last treatment | |
| Carvykti | Janssen Inc. | For the treatment of adult patients with multiple myeloma, who have received 1 to 3 prior lines of therapy including a proteasome inhibitor and an immunomodulatory agent, and who are refractory to lenalidomide. | |
| Calquence | AstraZeneca Canada Inc. | Indicated in combination with venetoclax for the treatment of patients with previously untreated CLL. | |
| Venclexta | AbbVie Corporation | Calquence, in combination with venetoclex, for the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL) |